WuXi Biologics and Harbour BioMed have entered into collaboration for the development and manufacturing of the former’s HCAb antibody.
The collaboration with WuXi Biologics will support the supply of Harbour's products for clinical trials under Investigational New Drug (IND) applications in China and worldwide.
Harbour BioMed CEO Jingsong Wang said: "In about a year's time, our scientists have moved our leading HCAb molecule into IND enabling stage. We are excited to collaborate with WuXi Biologics to accelerate further development of this molecule.
“This collaboration is aligned with our strategy to partner with industry leaders to bring forward innovative therapeutics that will help patients.”
WuXi Biologics CEO Chris Chen said: "Harbour's trust in WuXi Biologics to develop this novel format of HCAb is a strong testament of WuXi Biologics as a global leader in technology.
"We have enabled more than 20 complex molecules to the clinic including different bispecific formats, ADCs, fusion proteins and novel protein scaffolds. We aim to empower anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing."
Source: Company Press Release